LRRK2 inhibitors have been produced in several generations, with each iteration improving in potency, selectivity, and brain penetrability. LRRK2 inhibitors may thus be employed in clinical practice for Parkinson's disease therapy in the future. However, their efficacy and safety are still issues that must be solved before they may be used. More study is needed to understand the activities of LRRK2 and broaden its applicability in Parkinson's disease treatment, and even if LRRK2 inhibitors show helpful and safe, the time at which LRRK2 inhibition should be started remains unknown. It is uncertain if inhibiting LRRK2 can prevent or reverse the loss of DA neurons in the midbrain.